Abstract:Question How do familial hypercholesterolemia (FH) genetic variants modify coronary heart disease (CHD) risk among adults with moderate (LDL-C 130-189 mg/dL) and severe (LDL-C≥190 mg/dL) hypercholesterolemia? Findings In this pooled cohort study of 21 426 participants followed up with for a median of 18 years, FH variants were associated with a 2-fold higher CHD risk, even among individuals with moderately elevated LDL-C. The increased CHD risk appeared to be largely explained by the substantially higher lifetime cumulative LDL-C exposure in those with an FH variant vs those without. Meaning The findings suggest that genetic testing for FH may help refine risk stratification beyond LDL-C alone; clinical research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening. Importance Familial hypercholesterolemia (FH) is a genetic disorder that often results in severely high low-density lipoprotein cholesterol (LDL-C) and high risk of premature coronary heart disease (CHD). However, the impact of FH variants on CHD risk among individuals with moderately elevated LDL-C is not well quantified. Objective To assess CHD risk associated with FH variants among individuals with moderately (130-189 mg/dL) and severely (≥190 mg/dL) elevated LDL-C and to quantify excess CHD deaths attributable to FH variants in US adults. Design, Setting, and Participants A total of 21 426 individuals without preexisting CHD from 6 US cohort studies (Atherosclerosis Risk in Communities study, Coronary Artery Risk Development in Young Adults study, Cardiovascular Health Study, Framingham Heart Study Offspring cohort, Jackson Heart Study, and Multi-Ethnic Study of Atherosclerosis) were included, 63 of whom had an FH variant. Data were collected from 1971 to 2018, and the median (IQR) follow-up was 18 (13-28) years. Data were analyzed from March to May 2023. Exposures LDL-C, cumulative past LDL-C, FH variant status. Main Outcomes and Measures Cox proportional hazards models estimated associations between FH variants and incident CHD. The Cardiovascular Disease Policy Model projected excess CHD deaths associated with FH variants in US adults. Results Of the 21 426 individuals without preexisting CHD (mean [SD] age 52.1 [15.5] years; 12 041 [56.2%] female), an FH variant was found in 22 individuals with moderately elevated LDL-C (0.3%) and in 33 individuals with severely elevated LDL-C (2.5%). The adjusted hazard ratios for incident CHD comparing those with and without FH variants were 2.9 (95% CI, 1.4-6.0) and 2.6 (95% CI, 1.4-4.9) among individuals with moderately and severely elevated LDL-C, respectively. The association between FH variants and CHD was slightly attenuated when further adjusting for baseline LDL-C level, whereas the association was no longer statistically significant after adjusting for cumulative past LDL-C exposure. Among US adults 20 years and older with no history of CHD and LDL-C 130 mg/dL or higher, more than 417 000 carry an FH variant and were projected to experience more than 12 000 excess CHD deaths in those with moderately elevated LDL-C and 15 000 in those with severely elevated LDL-C compared with individuals without an FH variant. Conclusions and Relevance In this pooled cohort study, the presence of FH variants was associated with a 2-fold higher CHD risk, even when LDL-C was only moderately elevated. The increased CHD risk appeared to be largely explained by the higher cumulative LDL-C exposure in individuals with an FH variant compared to those without. Further research is needed to assess the value of adding genetic testing to traditional phenotypic FH screening.

Reproductive Carrier Screening: Identifying Families at Risk for Familial Hypercholesterolemia in the United States

Carrier Burden of over 300 Diseases in Han Chinese Identified by Expanded Carrier Testing of 300 Couples Using Assisted Reproductive Technology.

Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia.

LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia

Functional Analysis of 3 ′ UTR Variants at the LDLR and PCSK9 Genes in Patients with Familial Hypercholesterolemia

Novel LDLR variants affecting low density lipoprotein metabolism identified in familial hypercholesterolemia

GW24-e3589 A novel mutation 1587_1588 del2 of the low-density lipoprotein receptor gene associated with familial hypercholesterolemia in a Chinese family

Enhancing Familial Hypercholesterolemia Detection in South Korea: A Targeted Screening Approach Integrating National Program and Genetic Cascade Screening

A Capillary Electrophoresis-Based Multiplex PCR Assay for Expanded Carrier Screening in the Eastern Han Chinese Population

TARGETED SEQUENCING REVEAL TWO PATHOGENIC MUTATIONS IN LDLR AND APOE GENES IN PATIENT WITH FAMILY HYPERCHOLESTEROLEMIA: CASE REPORT

Genetic identification of familial hypercholesterolemia within a single U.S. health care system

Effects of Genetic Variants Associated with Familial Hypercholesterolemia on Low-Density Lipoprotein-Cholesterol Levels and Cardiovascular Outcomes in the Million Veteran Program.

Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol

Identification of a Novel Mutation at the Point of Low Density Lipoprotein Receptor Gene from a Subject with Familial Hypercholesterolemia

Identification of a Novel Pathogenic LDLR Mutation in a Chinese Family with Familial Hypercholesterolemia

Large-Scale CRISPR Screen of LDLR Pathogenic Variants

Genetic analysis and management of a familial hypercholesterolemia pedigree with polygenic variants: Case report

Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families

A Rapid and Scalable Multiplex PCR-Based Next-Generation Amplicon Sequencing Method for Familial Hypercholesterolemia Genetic Screening

Large-scale functional characterization of low-density lipoprotein receptor gene variants improves risk assessment in cardiovascular disease

Challenges and opportunities for identifying people with Familial hypercholesterolaemia in the UK: Evidence from the National FH PASS database